Efficacia di omalizumab

Pooled analysis della casistica italiana

Translated title of the contribution: Effects of omalizumab: Pooled analysis on kalian experiences

L. Allegra, F. Cetta, S. Della Patrona, T. La Spina, G. Petrigni

Research output: Contribution to journalArticle

Abstract

Omalizumab, humanized recombining monoclonal antibody of murine origin, able to bind IgEs, consequently blocking their interaction with mastcells and basophyls, has been proven effective in the treatment of persistent moderate- to-severe (specially at high risk), IgE-mediated, asthma in adults and adolescents non-adequately 8or not at all) controlled by the best possible therapy. This Journal, in consideration of the high originality of such novel therapeutic proposal, has published in the last two years 32 contributions of Italian Authors, consisting of case reports on the effect of omalizumab in patients suffering from asthma characterised by the over mentioned characteristics. The 32 articles present 42 adult or elderly patients. The present is a pooled analysis on most important clinical, functional, pharmacological and social effects of such therapy. Sex, age and diagnosis of the patients are taken into consideration, besides to the following clinical variables: onset of improvements, symptomatologic changes, hospitalisations and emergency therapy, quality of life,use of steroids, additive use of salbutamol as "rescue" therapy, other (non-steroidal) maintenance treatments, FEV 1. We remark that, since the patients are characterised by a relatively "old" age (49 yrs) which is often linked with inveterate asthma and due to the frequent hospitalisations and emergency visits, it can be confirmed that the patients are in general sekected between those corresponding to clinical criteria of moderate-to-severe persistent uncontrolled asthma. Particular evidence was attributed to improved quality of life, to the possibility of reducing (sometimes withdrawing) steroids and rescue salbutamol. Improvement of bronchial patency, evaluated thank to FEV 1 (comparison of post/pre-omalizumab FEV 1) shows clear-cut evidence in 77%, poor or no change in 23%, with +28.4% FEVi average (p>0.001). Onset of improvement has an average time of 7.8 weeks following omalizumab introduction in therapy, but is generally much earlier, residing 4 weeks in the majority of cases.

Original languageItalian
Pages (from-to)83-90
Number of pages8
JournalGIMT - Giornale Italiano delle Malattie del Torace
Volume62
Issue number2
Publication statusPublished - 2008

Fingerprint

Asthma
Albuterol
Therapeutics
Hospitalization
Steroids
Quality of Life
Antibodies, Monoclonal, Humanized
Emergency Treatment
Omalizumab
Immunoglobulin E
Emergencies
Pharmacology

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Allegra, L., Cetta, F., Patrona, S. D., La Spina, T., & Petrigni, G. (2008). Efficacia di omalizumab: Pooled analysis della casistica italiana. GIMT - Giornale Italiano delle Malattie del Torace, 62(2), 83-90.

Efficacia di omalizumab : Pooled analysis della casistica italiana. / Allegra, L.; Cetta, F.; Patrona, S. Della; La Spina, T.; Petrigni, G.

In: GIMT - Giornale Italiano delle Malattie del Torace, Vol. 62, No. 2, 2008, p. 83-90.

Research output: Contribution to journalArticle

Allegra, L, Cetta, F, Patrona, SD, La Spina, T & Petrigni, G 2008, 'Efficacia di omalizumab: Pooled analysis della casistica italiana', GIMT - Giornale Italiano delle Malattie del Torace, vol. 62, no. 2, pp. 83-90.
Allegra L, Cetta F, Patrona SD, La Spina T, Petrigni G. Efficacia di omalizumab: Pooled analysis della casistica italiana. GIMT - Giornale Italiano delle Malattie del Torace. 2008;62(2):83-90.
Allegra, L. ; Cetta, F. ; Patrona, S. Della ; La Spina, T. ; Petrigni, G. / Efficacia di omalizumab : Pooled analysis della casistica italiana. In: GIMT - Giornale Italiano delle Malattie del Torace. 2008 ; Vol. 62, No. 2. pp. 83-90.
@article{5523094059b44b6a980b6bfb120ecc0f,
title = "Efficacia di omalizumab: Pooled analysis della casistica italiana",
abstract = "Omalizumab, humanized recombining monoclonal antibody of murine origin, able to bind IgEs, consequently blocking their interaction with mastcells and basophyls, has been proven effective in the treatment of persistent moderate- to-severe (specially at high risk), IgE-mediated, asthma in adults and adolescents non-adequately 8or not at all) controlled by the best possible therapy. This Journal, in consideration of the high originality of such novel therapeutic proposal, has published in the last two years 32 contributions of Italian Authors, consisting of case reports on the effect of omalizumab in patients suffering from asthma characterised by the over mentioned characteristics. The 32 articles present 42 adult or elderly patients. The present is a pooled analysis on most important clinical, functional, pharmacological and social effects of such therapy. Sex, age and diagnosis of the patients are taken into consideration, besides to the following clinical variables: onset of improvements, symptomatologic changes, hospitalisations and emergency therapy, quality of life,use of steroids, additive use of salbutamol as {"}rescue{"} therapy, other (non-steroidal) maintenance treatments, FEV 1. We remark that, since the patients are characterised by a relatively {"}old{"} age (49 yrs) which is often linked with inveterate asthma and due to the frequent hospitalisations and emergency visits, it can be confirmed that the patients are in general sekected between those corresponding to clinical criteria of moderate-to-severe persistent uncontrolled asthma. Particular evidence was attributed to improved quality of life, to the possibility of reducing (sometimes withdrawing) steroids and rescue salbutamol. Improvement of bronchial patency, evaluated thank to FEV 1 (comparison of post/pre-omalizumab FEV 1) shows clear-cut evidence in 77{\%}, poor or no change in 23{\%}, with +28.4{\%} FEVi average (p>0.001). Onset of improvement has an average time of 7.8 weeks following omalizumab introduction in therapy, but is generally much earlier, residing 4 weeks in the majority of cases.",
keywords = "Clinical improvement, Fevi improvement, Improvement onset, Omalizumab, Pooled analysis",
author = "L. Allegra and F. Cetta and Patrona, {S. Della} and {La Spina}, T. and G. Petrigni",
year = "2008",
language = "Italian",
volume = "62",
pages = "83--90",
journal = "GIMT - Giornale Italiano delle Malattie del Torace",
issn = "1127-0810",
publisher = "Giornale Italiano Delle Malattie del Torace",
number = "2",

}

TY - JOUR

T1 - Efficacia di omalizumab

T2 - Pooled analysis della casistica italiana

AU - Allegra, L.

AU - Cetta, F.

AU - Patrona, S. Della

AU - La Spina, T.

AU - Petrigni, G.

PY - 2008

Y1 - 2008

N2 - Omalizumab, humanized recombining monoclonal antibody of murine origin, able to bind IgEs, consequently blocking their interaction with mastcells and basophyls, has been proven effective in the treatment of persistent moderate- to-severe (specially at high risk), IgE-mediated, asthma in adults and adolescents non-adequately 8or not at all) controlled by the best possible therapy. This Journal, in consideration of the high originality of such novel therapeutic proposal, has published in the last two years 32 contributions of Italian Authors, consisting of case reports on the effect of omalizumab in patients suffering from asthma characterised by the over mentioned characteristics. The 32 articles present 42 adult or elderly patients. The present is a pooled analysis on most important clinical, functional, pharmacological and social effects of such therapy. Sex, age and diagnosis of the patients are taken into consideration, besides to the following clinical variables: onset of improvements, symptomatologic changes, hospitalisations and emergency therapy, quality of life,use of steroids, additive use of salbutamol as "rescue" therapy, other (non-steroidal) maintenance treatments, FEV 1. We remark that, since the patients are characterised by a relatively "old" age (49 yrs) which is often linked with inveterate asthma and due to the frequent hospitalisations and emergency visits, it can be confirmed that the patients are in general sekected between those corresponding to clinical criteria of moderate-to-severe persistent uncontrolled asthma. Particular evidence was attributed to improved quality of life, to the possibility of reducing (sometimes withdrawing) steroids and rescue salbutamol. Improvement of bronchial patency, evaluated thank to FEV 1 (comparison of post/pre-omalizumab FEV 1) shows clear-cut evidence in 77%, poor or no change in 23%, with +28.4% FEVi average (p>0.001). Onset of improvement has an average time of 7.8 weeks following omalizumab introduction in therapy, but is generally much earlier, residing 4 weeks in the majority of cases.

AB - Omalizumab, humanized recombining monoclonal antibody of murine origin, able to bind IgEs, consequently blocking their interaction with mastcells and basophyls, has been proven effective in the treatment of persistent moderate- to-severe (specially at high risk), IgE-mediated, asthma in adults and adolescents non-adequately 8or not at all) controlled by the best possible therapy. This Journal, in consideration of the high originality of such novel therapeutic proposal, has published in the last two years 32 contributions of Italian Authors, consisting of case reports on the effect of omalizumab in patients suffering from asthma characterised by the over mentioned characteristics. The 32 articles present 42 adult or elderly patients. The present is a pooled analysis on most important clinical, functional, pharmacological and social effects of such therapy. Sex, age and diagnosis of the patients are taken into consideration, besides to the following clinical variables: onset of improvements, symptomatologic changes, hospitalisations and emergency therapy, quality of life,use of steroids, additive use of salbutamol as "rescue" therapy, other (non-steroidal) maintenance treatments, FEV 1. We remark that, since the patients are characterised by a relatively "old" age (49 yrs) which is often linked with inveterate asthma and due to the frequent hospitalisations and emergency visits, it can be confirmed that the patients are in general sekected between those corresponding to clinical criteria of moderate-to-severe persistent uncontrolled asthma. Particular evidence was attributed to improved quality of life, to the possibility of reducing (sometimes withdrawing) steroids and rescue salbutamol. Improvement of bronchial patency, evaluated thank to FEV 1 (comparison of post/pre-omalizumab FEV 1) shows clear-cut evidence in 77%, poor or no change in 23%, with +28.4% FEVi average (p>0.001). Onset of improvement has an average time of 7.8 weeks following omalizumab introduction in therapy, but is generally much earlier, residing 4 weeks in the majority of cases.

KW - Clinical improvement

KW - Fevi improvement

KW - Improvement onset

KW - Omalizumab

KW - Pooled analysis

UR - http://www.scopus.com/inward/record.url?scp=65449134791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65449134791&partnerID=8YFLogxK

M3 - Articolo

VL - 62

SP - 83

EP - 90

JO - GIMT - Giornale Italiano delle Malattie del Torace

JF - GIMT - Giornale Italiano delle Malattie del Torace

SN - 1127-0810

IS - 2

ER -